Wall Street analyst estimates for NeuroPace, Inc. (NPCE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.11 | ||
| 2026-08-11 | $-0.18 | $-0.22 | +17.4% |
| 2026-05-12 | $-0.20 | $-0.19 | -5.3% |
| 2026-03-03 | $-0.08 | $-0.14 | +42.9% |
| 2025-11-04 | $-0.11 | $-0.20 | +45.0% |
| 2025-08-12 | $-0.26 | $-0.24 | -8.3% |
| 2025-05-13 | $-0.21 | $-0.26 | +19.2% |
| 2025-03-04 | $-0.18 | $-0.25 | +28.0% |
Valuation Ratios
| Price / Book | 39.18 |
| EV / EBITDA | -43.63 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $37.0M | $41.1M | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M |
| Cost of Revenue | $10.5M | $10.9M | $11.7M | $13.0M | $17.3M | $20.8M | $22.8M |
| Gross Profit | $26.5M | $30.3M | $33.4M | $32.5M | $48.1M | $59.1M | $77.2M |
| Research & Development | $18.3M | $15.7M | $18.2M | $21.9M | $20.8M | $23.7M | $27.9M |
| Selling, General & Admin | $30.2M | $27.6M | $39.0M | $51.3M | $54.5M | $57.1M | $65.7M |
| Operating Expenses | $48.5M | $43.3M | $57.2M | $73.3M | $75.3M | $80.8M | $93.6M |
| Operating Income | -$22.0M | -$13.1M | -$23.7M | -$40.8M | -$27.2M | -$21.7M | -$16.3M |
| EBITDA | -$20.1M | -$12.5M | -$28.4M | -$36.6M | -$22.8M | -$16.6M | -$12.1M |
| Interest Expense | $9.5M | $11.5M | $7.4M | $7.5M | $8.5M | $8.8M | $7.5M |
| Pre-tax Income | -$30.0M | -$24.3M | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$30.0M | -$24.3M | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M |
| EPS | $-2.70 | $-2.17 | $-2.17 | $-1.91 | $-1.27 | $-0.93 | $-0.66 |
| EPS (Diluted) | $-2.70 | $-2.17 | $-2.17 | $-1.91 | $-1.27 | $-0.93 | $-0.66 |
| Shares Outstanding (Diluted) | $11.1M | $11.1M | $16.6M | $24.6M | $25.9M | $29.1M | $32.7M |
Price
| Price | $14.10 |
| Market Cap | $481M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALDX · BWAY · CERS · CVRX · DCTH · GNLX · MASS
Explore sector: Healthcare · Medical - Devices
More sections of NPCE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks